NCT04483375View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 24, 2020

Primary Completion Date

November 17, 2020

Study Completion Date

November 17, 2020

Conditions

Coronavirus Disease 2019(COVID-19)

Interventions

BIOLOGICAL

SCTA01

recombinant humanized anti-SARS-CoV-2 monoclonal antibody

OTHER

Placebo

Trial Locations (1)

100038

Beijing SHIJITAN Hospital, Beijing

All Listed Sponsors

lead

Sinocelltech Ltd.

INDUSTRY

NCT04483375 - Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects | Biotech Hunter | Biotech Hunter